Linea Energy has closed project debt financing and secured preferred equity for its 250 MW / 500 MWh Mesa View battery energy storage system in Texas. The financing includes a construction-to-term loan, tax equity bridge loan, and letter of credit, with Norddeutsche Landesbank and Texas Capital as lenders, and D.E. Shaw Renewable Investments providing preferred equity. The project, expected to be operational in 2027, will supply dispatchable power to the ERCOT market, supporting grid reliability and the energy transition. This milestone highlights Linea's growing platform and ability to deliver large-scale clean energy infrastructure projects.
Linea Energy's Mesa View battery project financing is the subject, with Pluang's Energy sector data providing market context. As of Oct 02, 2026 03:26 WIB, 21 of 38 priced US Energy stocks rose while 17 fell. Valero Energy Corporation (VLO) led with a 5.35% gain at USD 408.35 and a typical hold time of 56 days, contrasted by Occidental Petroleum Corporation (OXY) at USD 57.82 with 100% buy order activity and a longer hold time of 91 days, while Enphase Energy Inc (ENPH) traded at USD 33.00 with a 3.68% increase and mixed order activity.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
